1. A 54-year-old immunocompromised patient with esophageal candidiasis has been receiving fluconazole 400 mg IV daily for five days and is clinically improving with tolerating oral intake. The team plans to transition to oral fluconazole. What dose adjustment is required when switching from IV to oral fluconazole, and what pharmacokinetic property justifies this decision?
A) Reduce the oral dose to 200 mg daily because hepatic first-pass metabolism reduces oral bioavailability to approximately 50%, requiring a compensatory dose reduction to avoid accumulation
B) Increase the oral dose to 800 mg daily because the oral formulation must overcome partial degradation in the gastric acid environment and incomplete intestinal absorption, requiring dose doubling to achieve equivalent plasma levels
C) No dose adjustment is required; oral fluconazole bioavailability is approximately 90% and is not significantly affected by food, gastric pH, or acid-suppressing medications, making IV-to-oral conversion at the same dose clinically reliable
D) Switch to fluconazole oral suspension rather than tablet because tablet formulations are poorly absorbed in immunocompromised patients due to reduced intestinal mucosal integrity
E) Reduce the oral dose to 300 mg daily and monitor plasma concentrations because oral bioavailability varies unpredictably between 60 and 90% across individual patients and cannot be assumed without therapeutic drug monitoring
ANSWER: C
Rationale:
Option C is correct. Fluconazole oral bioavailability is approximately 90% — among the highest of any systemic antifungal. This near-complete absorption is independent of food intake, gastric pH, and acid-suppressing medications (proton pump inhibitors, H2 receptor antagonists), which sharply distinguishes fluconazole from itraconazole capsules. Because bioavailability is so high and consistent, IV-to-oral conversion requires no dose adjustment; the oral dose is identical to the IV dose. This property gives fluconazole a substantial pharmacoeconomic and logistical advantage: IV therapy can be discontinued as soon as the patient tolerates oral intake without sacrificing drug exposure.
Option A: Option A is incorrect; fluconazole does not undergo significant hepatic first-pass metabolism. Its high oral bioavailability reflects passive intestinal absorption with minimal pre-systemic elimination; there is no basis for reducing the dose.
Option B: Option B is incorrect; fluconazole tablets are not degraded in the stomach and absorption is not impaired by gastric acid. Dose doubling is not required and would expose the patient to supratherapeutic concentrations.
Option D: Option D is incorrect; standard oral fluconazole tablets or capsules are reliably absorbed in immunocompromised patients. There is no pharmacokinetic basis for preferring a suspension formulation, and this is not standard practice.
Option E: Option E is incorrect; fluconazole oral bioavailability is consistently high across patients — it is not unpredictably variable. Therapeutic drug monitoring is not required for fluconazole in standard clinical use; TDM is primarily reserved for itraconazole, voriconazole, and posaconazole.
2. A 62-year-old patient with mild-to-moderate pulmonary histoplasmosis is prescribed itraconazole capsules 200 mg twice daily. She also takes lansoprazole 30 mg daily for Barrett's esophagus. A steady-state itraconazole trough level drawn after 14 days of therapy is reported as less than 0.1 mcg/mL. Which explanation best accounts for this subtherapeutic result?
A) Lansoprazole, a proton pump inhibitor (PPI), raises gastric pH and severely impairs itraconazole capsule dissolution; capsule absorption requires an acidic gastric environment and the presence of food-stimulated bile, making PPI co-administration a recognized cause of near-zero itraconazole bioavailability from capsules
B) Lansoprazole inhibits hepatic CYP3A4 (cytochrome P450 3A4) and paradoxically increases itraconazole metabolism, reducing plasma concentrations despite adequate capsule dissolution
C) Itraconazole capsule bioavailability is uniformly low (below 20%) in all patients regardless of gastric pH, and the subtherapeutic level reflects the expected pharmacokinetics of the capsule formulation even under optimal conditions
D) The patient's Barrett's esophagus causes malabsorption of lipophilic drugs due to metaplastic changes in the esophageal mucosa, reducing itraconazole absorption independent of gastric pH
E) Lansoprazole chelates the triazole ring of itraconazole in the gastric lumen, forming an insoluble complex that prevents intestinal absorption of the active drug
ANSWER: A
Rationale:
Option A is correct. Itraconazole capsules contain itraconazole coated on sugar spheres whose dissolution requires an acidic gastric environment (pH below 3 to 4) and the presence of food to stimulate acid secretion and bile release. Proton pump inhibitors (PPIs) such as lansoprazole, omeprazole, and pantoprazole suppress gastric acid secretion, raising intragastric pH substantially. Under these conditions, itraconazole capsule dissolution is severely impaired and oral bioavailability can fall to near zero — consistent with the trough of less than 0.1 mcg/mL reported here, well below the therapeutic target of above 1.0 mcg/mL for treatment. The correct clinical response is to switch to the itraconazole oral solution, which uses hydroxypropyl-beta-cyclodextrin as a solubilizing vehicle and achieves bioavailability that is far less dependent on gastric pH; the solution is taken fasting.
Option B: Option B is incorrect; lansoprazole is a CYP2C19 substrate and may mildly inhibit CYP2C19, but it is not a clinically significant CYP3A4 inhibitor. CYP3A4 inhibition would increase itraconazole levels, not decrease them; this is the opposite of what is observed.
Option C: Option C is incorrect; under optimal conditions (full meal, normal gastric acidity, no acid suppression), itraconazole capsule bioavailability reaches approximately 55% — not uniformly below 20%. The problem in this case is acid suppression, not inherently poor capsule formulation performance.
Option D: Option D is incorrect; Barrett's esophagus involves columnar metaplasia of the distal esophageal mucosa and does not cause intestinal malabsorption of lipophilic drugs. Itraconazole absorption occurs primarily in the upper small intestine, not the esophagus.
Option E: Option E is incorrect; chemical chelation of itraconazole by lansoprazole in the gastric lumen does not occur. The interaction is entirely pH-mediated through impaired capsule dissolution, not through direct drug-drug chemical binding.
3. A patient receiving multiple medications is started on fluconazole 200 mg daily. The clinical pharmacist reviews the medication list for interaction risk. Which statement most precisely describes fluconazole's cytochrome P450 (CYP) inhibition profile and its clinical implications for co-administered substrates?
A) Fluconazole is a potent inhibitor of CYP3A4 (cytochrome P450 3A4) and a moderate inhibitor of CYP2C9 (cytochrome P450 2C9); its most consequential interactions are with immunosuppressants metabolized by CYP3A4 including tacrolimus and cyclosporine
B) Fluconazole is a selective inhibitor of CYP1A2 (cytochrome P450 1A2) and CYP2D6 (cytochrome P450 2D6), producing clinically significant increases in theophylline and tricyclic antidepressant plasma concentrations
C) Fluconazole inhibits all hepatic CYP enzymes non-selectively at therapeutic concentrations; the clinical pharmacist should review every co-administered drug for potential interaction regardless of the metabolic pathway involved
D) Fluconazole is a weak inhibitor of CYP3A4 only; its interaction profile is minimal at standard doses and clinically significant interactions occur only with doses above 800 mg daily
E) Fluconazole is a potent inhibitor of CYP2C9 (cytochrome P450 2C9) and a moderate inhibitor of CYP3A4 (cytochrome P450 3A4) and CYP2C19 (cytochrome P450 2C19); it does not significantly inhibit CYP1A2 or CYP2D6, and its highest-priority interactions include warfarin (CYP2C9 substrate), phenytoin (CYP2C9/CYP2C19 substrate), and calcineurin inhibitors (CYP3A4 substrates)
ANSWER: E
Rationale:
Option E is correct. Fluconazole's CYP inhibition profile is defined by potent CYP2C9 inhibition, moderate CYP3A4 inhibition, and moderate CYP2C19 inhibition. It does not significantly inhibit CYP1A2 or CYP2D6. This profile predicts the highest-priority clinical interactions: warfarin (S-warfarin is a CYP2C9 substrate — fluconazole routinely causes INR increases of 2- to 3-fold), phenytoin (a CYP2C9 and CYP2C19 substrate — fluconazole can cause phenytoin toxicity), oral hypoglycemics (tolbutamide, glipizide are CYP2C9 substrates), and calcineurin inhibitors including tacrolimus and cyclosporine (CYP3A4 substrates — fluconazole increases tacrolimus concentrations 2- to 4-fold, smaller than itraconazole but still clinically significant). Understanding which isoforms are inhibited allows the pharmacist to triage the medication list rather than reviewing every drug indiscriminately.
Option A: Option A is incorrect; this description inverts the primary inhibition profile. Fluconazole is a potent CYP2C9 inhibitor and a moderate CYP3A4 inhibitor, not the reverse. Itraconazole (not fluconazole) is a potent CYP3A4 inhibitor whose highest-consequence calcineurin inhibitor interactions are more severe.
Option B: Option B is incorrect; fluconazole does not significantly inhibit CYP1A2 or CYP2D6 at therapeutic concentrations. Interactions with theophylline (CYP1A2 substrate) and most tricyclic antidepressants (CYP2D6 substrates) are not primary concerns with fluconazole.
Option C: Option C is incorrect; fluconazole has a specific and predictable CYP inhibition profile, not non-selective pan-CYP inhibition. Clinically significant interactions are concentrated around CYP2C9 and CYP3A4 substrates.
Option D: Option D is incorrect; fluconazole inhibits CYP2C9 potently and CYP3A4 and CYP2C19 moderately at standard therapeutic doses of 100 to 400 mg daily. Clinically significant warfarin and calcineurin inhibitor interactions occur at routine doses, not only above 800 mg.
4. A liver transplant recipient on tacrolimus and warfarin develops blastomycosis requiring systemic antifungal therapy. Itraconazole oral solution is selected. Which statement most precisely describes itraconazole's enzyme and transporter inhibition profile, and how it differs from fluconazole?
A) Itraconazole and fluconazole have identical CYP inhibition profiles; both are potent CYP2C9 inhibitors and moderate CYP3A4 inhibitors, so the clinical team should manage drug interactions identically for each agent
B) Itraconazole is a potent inhibitor of CYP3A4 (cytochrome P450 3A4) and P-glycoprotein (P-gp) efflux transport, but does not significantly inhibit CYP2C9 or CYP2C19; this profile causes far greater tacrolimus concentration increases than fluconazole but produces less warfarin interaction than fluconazole
C) Itraconazole is a selective inhibitor of CYP2C9 and CYP2C19, making it more dangerous than fluconazole specifically for warfarin co-administration but safer than fluconazole for tacrolimus co-administration
D) Itraconazole inhibits CYP3A4 in the intestinal wall only, not in hepatocytes; therefore it increases the bioavailability of oral CYP3A4 substrates but does not affect the clearance of IV-administered CYP3A4 substrates such as IV tacrolimus
E) Itraconazole is a pan-CYP inhibitor with equivalent potency across all major CYP isoforms; its interaction profile cannot be predicted from isoform specificity and requires case-by-case therapeutic drug monitoring for every co-administered agent
ANSWER: B
Rationale:
Option B is correct. Itraconazole is a potent inhibitor of CYP3A4 and P-glycoprotein (P-gp), but does not significantly inhibit CYP2C9 or CYP2C19. This profile creates distinct and clinically critical differences from fluconazole. Tacrolimus is a CYP3A4 and P-gp substrate; itraconazole inhibits both clearance mechanisms simultaneously, producing 5- to 10-fold or greater increases in tacrolimus blood concentrations — far more severe than the 2- to 4-fold increase caused by fluconazole's moderate CYP3A4 inhibition. In this patient, the tacrolimus dose must be proactively reduced by 50 to 75% with daily trough monitoring. Conversely, warfarin interaction with itraconazole is less severe than with fluconazole: S-warfarin (the active enantiomer) is primarily metabolized by CYP2C9 — which itraconazole does not significantly inhibit — so INR elevation from itraconazole is less dramatic than from fluconazole, though R-warfarin (a CYP3A4 substrate) is affected to some degree. This underscores the importance of knowing the specific isoforms inhibited by each azole rather than treating the class as a uniform interaction risk.
Option A: Option A is incorrect; itraconazole and fluconazole have fundamentally different CYP inhibition profiles. Fluconazole is a potent CYP2C9 inhibitor and moderate CYP3A4 inhibitor; itraconazole is a potent CYP3A4 and P-gp inhibitor but does not significantly inhibit CYP2C9. Managing these agents as interchangeable from an interaction standpoint would be clinically dangerous.
Option C: Option C is incorrect; this describes fluconazole's profile (CYP2C9-dominant inhibitor), not itraconazole's. Itraconazole does not significantly inhibit CYP2C9 or CYP2C19; its interaction risk is concentrated on CYP3A4 and P-gp substrates.
Option D: Option D is incorrect; itraconazole inhibits CYP3A4 in both the intestinal wall and hepatocytes. While the intestinal (first-pass) component contributes importantly to increased bioavailability of oral substrates, hepatic CYP3A4 inhibition also reduces systemic clearance of IV CYP3A4 substrates including IV tacrolimus.
Option E: Option E is incorrect; itraconazole has a specific isoform profile (CYP3A4 and P-gp dominant), not pan-CYP inhibition. Predicting interactions from isoform substrate data is both possible and essential for safe prescribing.
5. Blood cultures from a neutropenic patient with acute leukemia grow Candida krusei. The microbiology laboratory reports an MIC (minimum inhibitory concentration) of 8 mcg/mL for fluconazole and labels the isolate "susceptible-dose-dependent." A resident proposes using high-dose fluconazole 800 mg daily to treat the infection. Which response is most appropriate?
A) The resident's plan is reasonable; susceptibility-dose-dependent (SDD) interpretations indicate that achieving higher fluconazole plasma concentrations will overcome the resistance mechanism in C. krusei, making 800 mg daily an effective strategy
B) The plan is acceptable only if therapeutic drug monitoring confirms fluconazole plasma concentrations above 16 mcg/mL; if this concentration cannot be reliably achieved, switch to an echinocandin
C) The MIC of 8 mcg/mL is within the susceptible range for fluconazole; standard dosing at 400 mg daily is adequate and dose escalation is unnecessary
D) Candida krusei has intrinsic fluconazole resistance that is present in all isolates regardless of susceptibility testing results; the MIC value and SDD designation should not be used to guide treatment, and fluconazole should never be used for C. krusei infections regardless of reported in vitro susceptibility
E) High-dose fluconazole is appropriate as a bridge until echinocandin therapy can be arranged; short courses of 3 to 5 days at 800 mg daily are safe and effective for C. krusei given the urgency of neutropenic candidemia
ANSWER: D
Rationale:
Option D is correct. Candida krusei (now reclassified as Pichia kudriavzevii) has intrinsic fluconazole resistance present in all isolates, arising from a combination of low intrinsic affinity of the CYP51 enzyme for fluconazole and constitutive expression of CDR (Candida Drug Resistance) efflux transporters. This intrinsic resistance means that standard in vitro susceptibility testing with fluconazole is unreliable for predicting clinical response for this species. A reported "susceptible-dose-dependent" result for C. krusei is a laboratory artifact that should not guide clinical decision-making. Current IDSA guidelines and species-level pharmacology explicitly state that fluconazole should never be used for C. krusei infections regardless of in vitro susceptibility results. Echinocandins are the drug of choice.
Option A: Option A is incorrect; the susceptibility-dose-dependent (SDD) designation is meaningful for species where acquired resistance has shifted the MIC distribution (such as Candida glabrata), but for C. krusei the resistance is intrinsic and mechanistic — no achievable plasma concentration of fluconazole reliably overcomes it.
Option B: Option B is incorrect; therapeutic drug monitoring of fluconazole to target 16 mcg/mL is not an established strategy for treating C. krusei infections, and the premise that concentration escalation can overcome intrinsic resistance is not supported.
Option C: Option C is incorrect; the MIC of 8 mcg/mL for C. krusei does not fall within a fluconazole susceptible range for this species. Standard susceptibility breakpoints for fluconazole do not apply to C. krusei, which is intrinsically resistant.
Option E: Option E is incorrect; there is no evidence supporting high-dose fluconazole as a bridge therapy for C. krusei candidemia, and administering a drug with intrinsic resistance creates false confidence and delays effective antifungal therapy in a critically ill neutropenic patient.
6. A 70-year-old patient with stage 4 chronic kidney disease (CKD) — creatinine clearance (CrCl) estimated at 18 mL/min — develops cryptococcal meningitis and requires fluconazole consolidation therapy. Which statement about fluconazole pharmacokinetics and dosing in this patient is correct?
A) Fluconazole is excreted approximately 80% unchanged in the urine; in patients with CrCl below 50 mL/min, the maintenance dose should be reduced to 50% of the standard dose to prevent drug accumulation and concentration-related toxicity including QTc prolongation
B) Fluconazole undergoes complete hepatic metabolism prior to renal excretion; no dose adjustment is required in renal impairment because the drug is fully converted to inactive metabolites before it reaches the kidney
C) Fluconazole dose adjustment in CKD is unnecessary because the drug is efficiently removed by hemodialysis, and even if accumulation occurs between dialysis sessions, the next dialysis session will clear any excess drug
D) Fluconazole is primarily excreted by biliary elimination into the gut and undergoes extensive enterohepatic recirculation; renal impairment does not affect plasma half-life or require dose modification
E) Fluconazole is a highly protein-bound drug; in CKD, reduced albumin levels increase the free fraction sufficiently to compensate for reduced renal clearance, and the total plasma concentration target remains unchanged
ANSWER: A
Rationale:
Option A is correct. Fluconazole is excreted primarily in the urine — approximately 80% as unchanged parent drug, with the remainder as metabolites. Because renal clearance is the dominant elimination pathway, fluconazole half-life and plasma concentrations increase substantially as CrCl declines. In patients with CrCl below 50 mL/min who are not on dialysis, the standard recommendation is to use the normal loading dose on day 1 (to rapidly achieve therapeutic concentrations) followed by a maintenance dose reduced to 50% of the standard dose. For this patient with a CrCl of 18 mL/min, standard consolidation dosing of 400 mg daily would be adjusted to 200 mg daily after the loading dose. Failure to reduce the dose risks drug accumulation, prolonged QTc interval, and other concentration-dependent toxicities.
Option B: Option B is incorrect; fluconazole is not extensively metabolized prior to renal excretion. Approximately 80% of the administered dose appears in urine as unchanged drug, making renal function a critical determinant of drug clearance and requiring dose adjustment.
Option C: Option C is incorrect; while fluconazole is removed by hemodialysis (a full dialysis session removes approximately 50% of the drug), patients with CKD on chronic dialysis should receive a full dose after each dialysis session, not be managed by relying on dialysis to clear accumulation from an unadjusted dose. The rationale for dose adjustment is to prevent accumulation between dialysis sessions in non-dialysis CKD, not to rely on intermittent clearance.
Option D: Option D is incorrect; fluconazole is primarily renally eliminated, not via biliary excretion and enterohepatic recirculation. This description does not apply to fluconazole; the absence of significant enterohepatic recirculation is part of its pharmacokinetic profile.
Option E: Option E is incorrect; fluconazole has low protein binding (approximately 11 to 12%), not high protein binding. Changes in albumin in CKD do not meaningfully alter fluconazole's free fraction in a way that would compensate for impaired renal clearance.
7. A 71-year-old man with a history of ischemic cardiomyopathy (left ventricular ejection fraction 28%), New York Heart Association (NYHA) class III heart failure, and ongoing diuretic and beta-blocker therapy develops sporotrichosis. The infectious disease consultant considers itraconazole oral solution. Which statement most accurately characterizes the cardiac risk specific to itraconazole in this patient?
A) Itraconazole causes dose-dependent QTc prolongation via direct hERG (human ether-a-go-go-related gene) channel blockade; in patients with reduced ejection fraction the QTc threshold for toxicity is lower, requiring ECG (electrocardiogram) monitoring every 48 hours but not constituting a contraindication
B) Itraconazole's primary cardiac risk in heart failure patients is through CYP3A4-mediated elevation of co-administered beta-blocker concentrations, worsening bradycardia and precipitating cardiogenic shock; beta-blocker dose should be halved before initiating itraconazole
C) Itraconazole exerts a negative inotropic effect on the myocardium and is formally contraindicated by FDA labeling in patients with evidence of ventricular dysfunction, including congestive heart failure or a history of congestive heart failure; terbinafine or an alternative antifungal class should be considered
D) Itraconazole has no direct cardiac effects; the concern in heart failure patients is exclusively pharmacokinetic — reduced hepatic blood flow in low-output states reduces CYP3A4 activity and can cause itraconazole accumulation to hepatotoxic concentrations
E) Itraconazole causes hypertensive crisis in patients with structural heart disease by inhibiting endothelial CYP3A4 and reducing nitric oxide synthesis; this is the basis for its contraindication in heart failure
ANSWER: C
Rationale:
Option C is correct. Itraconazole has a well-characterized negative inotropic effect — it reduces myocardial contractility — that has caused and worsened congestive heart failure in patients receiving the drug. This is documented in postmarketing reports and clinical studies, and the FDA label for itraconazole carries a contraindication for its use in patients with evidence of ventricular dysfunction, including heart failure or a history of heart failure. For this patient with an ejection fraction of 28% and NYHA class III symptoms, itraconazole is formally contraindicated regardless of the antifungal indication. For sporotrichosis in a patient who cannot receive itraconazole, terbinafine is an acceptable oral alternative for lymphocutaneous disease; amphotericin B is available for severe cases.
Option A: Option A is incorrect; while fluconazole causes clinically important QTc prolongation through direct hERG channel blockade, this description does not capture itraconazole's primary cardiac risk. Itraconazole does have some QTc-prolonging potential (partly through indirect mechanisms), but the formal FDA contraindication for itraconazole in heart failure is based on its negative inotropic effect, not QTc prolongation, and it constitutes a contraindication rather than a monitoring requirement.
Option B: Option B is incorrect; while itraconazole does inhibit CYP3A4 and can increase concentrations of some co-administered drugs, beta-blockers are predominantly metabolized by CYP2D6, not CYP3A4. Halving the beta-blocker dose is not a standard recommendation, and this does not address the primary cardiac risk from itraconazole in this patient.
Option D: Option D is incorrect; itraconazole has documented direct cardiac effects (negative inotropy), not purely pharmacokinetic concerns in heart failure. While low cardiac output states can affect hepatic drug clearance, the contraindication in heart failure is pharmacodynamic, not pharmacokinetic.
Option E: Option E is incorrect; itraconazole does not cause hypertensive crisis via endothelial CYP3A4 inhibition and nitric oxide reduction. This mechanism is not pharmacologically established for itraconazole.
8. A clinical microbiology laboratory sequences the ERG11 gene of a Candida albicans bloodstream isolate and identifies a Y132H (tyrosine-132-to-histidine) point mutation. MIC testing shows fluconazole MIC of 32 mcg/mL, voriconazole MIC of 0.5 mcg/mL, and itraconazole MIC of 0.25 mcg/mL. Which statement best explains the pattern of differential azole susceptibility seen with this ERG11 mutation?
A) Y132H mutations selectively abolish CYP51 enzymatic activity entirely, preventing ergosterol synthesis; fluconazole MIC rises because the drug has no active enzyme to inhibit, while voriconazole and itraconazole remain active because they act on ERG11-independent targets
B) Y132H mutations upregulate CDR1 (Candida Drug Resistance 1) and CDR2 (Candida Drug Resistance 2) efflux pumps specifically for fluconazole; because the efflux pumps do not export voriconazole or itraconazole, those agents retain activity against this isolate
C) The Y132H mutation converts CYP51 from a demethylase to an alternative sterol reductase that is inhibited by voriconazole and itraconazole but not fluconazole, explaining the inverted susceptibility pattern
D) ERG11 mutations at all positions uniformly confer pan-azole resistance; the retained voriconazole and itraconazole susceptibility in this isolate indicates that a second unrelated resistance mechanism is counteracting the ERG11 mutation specifically for those agents
E) ERG11 point mutations alter the CYP51 active site geometry in ways that primarily reduce triazole nitrogen contact for fluconazole; voriconazole and itraconazole retain superior binding affinity at mutant CYP51 because their extended hydrophobic side chains make additional molecular contacts beyond the triazole nitrogen, partially compensating for the loss of the primary binding interaction
ANSWER: E
Rationale:
Option E is correct. Point mutations in ERG11 alter amino acid residues in the CYP51 active site that normally contact the azole molecule. The triazole nitrogen of all azole class members coordinates with the heme iron of CYP51 — this is the primary binding interaction shared across the azole class. ERG11 mutations at hot-spot positions such as Y132H, K143R, and F145L disrupt adjacent residues that contribute to drug binding, reducing affinity. However, voriconazole and itraconazole possess extended hydrophobic side chains (beyond the core triazole scaffold) that make additional molecular contacts with CYP51 residues outside the primary binding pocket. These additional contacts partially compensate for the loss of affinity caused by the mutation, maintaining adequate binding and enzyme inhibition at lower drug concentrations. Fluconazole, which has a simpler molecular structure with less capacity for these compensatory contacts, loses more binding affinity for the mutant enzyme, explaining the substantially higher fluconazole MIC compared to voriconazole and itraconazole. This pattern of selective fluconazole resistance with retained susceptibility to extended-spectrum azoles has important clinical implications: in patients with fluconazole-resistant C. albicans due to ERG11 mutations, switching to voriconazole may remain effective rather than automatically escalating to an echinocandin.
Option A: Option A is incorrect; ERG11 mutations reduce binding affinity but do not abolish CYP51 enzymatic activity. The enzyme retains catalytic function, and voriconazole and itraconazole do not act on ERG11-independent targets — all azoles share CYP51 as their mechanism.
Option B: Option B is incorrect; CDR1 and CDR2 efflux upregulation is a distinct resistance mechanism regulated by the TAC1 transcription factor and is not caused by ERG11 point mutations. CDR1/CDR2 upregulation would confer cross-resistance to all azoles, not selective fluconazole resistance.
Option C: Option C is incorrect; ERG11 mutations do not convert CYP51 to a sterol reductase, and voriconazole and itraconazole do not act on a different enzyme than fluconazole. All azoles share CYP51 as their target.
Option D: Option D is incorrect; not all ERG11 mutations confer pan-azole resistance. The selective fluconazole resistance with retained voriconazole and itraconazole susceptibility is a well-documented and mechanistically explained consequence of specific ERG11 mutations, not an artifact requiring an unexplained second counteracting mechanism.
9. A patient with hyperlipidemia on simvastatin 40 mg nightly and a recent cardiac stent develops invasive aspergillosis. Voriconazole is initiated, but the team considers using itraconazole for step-down therapy once the patient is clinically stable. Which statement best describes the pharmacokinetic interaction between itraconazole and simvastatin, and the recommended management?
A) Itraconazole inhibits CYP2C9 and substantially reduces simvastatin metabolism; the interaction is clinically insignificant at standard statin doses but requires dose halving to 20 mg nightly during itraconazole therapy
B) Itraconazole is a potent CYP3A4 (cytochrome P450 3A4) inhibitor; simvastatin and lovastatin are CYP3A4-metabolized statins with a known risk of severe myopathy and rhabdomyolysis when combined with potent CYP3A4 inhibitors, and this combination is contraindicated — pravastatin or rosuvastatin should be substituted as statins minimally dependent on CYP3A4 metabolism
C) All statins are equally affected by itraconazole because itraconazole inhibits the HMG-CoA reductase enzyme directly; statin dose should be reduced by 50% for all agents during itraconazole co-administration
D) The interaction between itraconazole and simvastatin is clinically manageable with weekly creatine kinase (CK) monitoring; simvastatin can be continued at the current dose with laboratory surveillance rather than substitution
E) Itraconazole reduces simvastatin bioavailability by inducing intestinal P-glycoprotein, lowering statin plasma concentrations; the clinical concern is loss of lipid-lowering efficacy during itraconazole therapy, not statin toxicity
ANSWER: B
Rationale:
Option B is correct. Simvastatin and lovastatin are CYP3A4-metabolized statins (pro-drugs activated and then metabolized via CYP3A4); their plasma concentrations are highly sensitive to potent CYP3A4 inhibitors. Itraconazole is a potent CYP3A4 and P-glycoprotein inhibitor — co-administration with simvastatin has been shown in pharmacokinetic studies to increase simvastatin acid (the active form) plasma exposure by 10- to 19-fold. At these concentrations, the risk of severe skeletal muscle toxicity including rhabdomyolysis is substantially elevated. This combination is contraindicated in prescribing information. The clinically correct action is to substitute a statin that is not primarily metabolized by CYP3A4: pravastatin (renally eliminated, minimal CYP metabolism) and rosuvastatin (primarily non-CYP elimination) are the preferred alternatives during azole therapy. Fluvastatin (CYP2C9 substrate) is another option but would interact with fluconazole.
Option A: Option A is incorrect; itraconazole does not significantly inhibit CYP2C9 and its primary interaction with simvastatin is via CYP3A4, not CYP2C9. More importantly, the interaction with simvastatin via CYP3A4 inhibition is not clinically insignificant — it is severe and contraindicated, not manageable by dose halving.
Option C: Option C is incorrect; itraconazole does not inhibit HMG-CoA reductase (that is the statin mechanism, not itraconazole's). Statins differ substantially in their CYP3A4 dependence: pravastatin, rosuvastatin, and fluvastatin are far less CYP3A4-dependent than simvastatin or lovastatin, and are not subject to the same degree of interaction.
Option D: Option D is incorrect; the simvastatin-itraconazole combination is contraindicated due to the magnitude of potential CYP3A4-mediated exposure increase and rhabdomyolysis risk. CK monitoring does not eliminate this risk; statin substitution is the correct management.
Option E: Option E is incorrect; itraconazole inhibits P-glycoprotein (which would increase, not decrease, simvastatin bioavailability by reducing efflux from enterocytes) and inhibits CYP3A4 (also increasing simvastatin levels). The risk is statin toxicity from elevated concentrations, not loss of efficacy from reduced concentrations.
10. A patient with AIDS (acquired immunodeficiency syndrome) and cryptococcal meningitis has completed two weeks of liposomal amphotericin B induction therapy. Blood cultures and CSF (cerebrospinal fluid) cultures are now sterile, and the team is transitioning to consolidation therapy with oral fluconazole 400 mg daily. A trainee asks why fluconazole is chosen over itraconazole for CNS (central nervous system) consolidation despite itraconazole's broader antifungal spectrum. Which pharmacokinetic explanation is most precise?
A) Fluconazole is actively transported across the blood-brain barrier by organic anion transporting polypeptide (OATP) carriers on the choroid plexus; itraconazole lacks this active CNS uptake mechanism and achieves only passive diffusion into the CSF
B) Fluconazole has a larger volume of distribution than itraconazole, resulting in higher drug concentrations in all tissue compartments including the CNS; itraconazole's smaller volume of distribution restricts it to the vascular space
C) Fluconazole achieves CNS penetration by inhibiting P-glycoprotein at the blood-brain barrier, preventing its own efflux from the CNS; itraconazole is a P-glycoprotein substrate that is actively effluxed from the CNS before reaching therapeutic concentrations
D) Fluconazole is relatively hydrophilic and has low protein binding of approximately 11 to 12%, resulting in a large free (unbound) fraction that crosses the blood-brain barrier by passive diffusion; CSF concentrations reach 70 to 90% of simultaneous plasma concentrations, while itraconazole's near-complete protein binding (approximately 99.8%) leaves a free fraction too small for adequate CNS penetration despite its large overall volume of distribution
E) Fluconazole's antifungal potency against Cryptococcus neoformans is intrinsically superior to itraconazole at equivalent plasma concentrations; the pharmacodynamic advantage accounts for the clinical preference independent of CNS distribution
ANSWER: D
Rationale:
Option D is correct. The basis for fluconazole's superior CNS penetration over itraconazole lies in two contrasting pharmacokinetic properties: protein binding and lipophilicity. Fluconazole is approximately 11 to 12% protein-bound, leaving approximately 88 to 89% as free drug available for passive diffusion across the blood-brain barrier. Combined with its relative hydrophilicity, fluconazole achieves CSF concentrations of 70 to 90% of simultaneous plasma concentrations — among the highest CNS penetration ratios of any systemic antifungal. Itraconazole, by contrast, is approximately 99.8% protein-bound; despite an enormous volume of distribution reflecting massive accumulation in lipophilic tissues (skin, nails, lungs, adipose), the free drug fraction available to cross into CSF is extremely small (approximately 0.2% of total drug). Protein-bound drug cannot cross membranes; it is the free fraction that determines CNS penetration. This explains why itraconazole, despite its large Vd, achieves negligible CSF concentrations and is contraindicated for CNS fungal infections.
Option A: Option A is incorrect; fluconazole's CNS penetration is by passive diffusion driven by free drug fraction, not active OATP transport. P-glycoprotein expressed at the blood-brain barrier limits CNS entry of many drugs, but fluconazole is not a significant P-gp substrate and its CNS penetration is passive diffusion-driven.
Option B: Option B is incorrect; this reverses the pharmacokinetic relationship. Itraconazole has a far larger volume of distribution (approximately 11 L/kg) than fluconazole (approximately 0.7 L/kg), yet itraconazole achieves far worse CNS penetration. Volume of distribution reflects tissue accumulation broadly, not CNS penetration specifically.
Option C: Option C is incorrect; fluconazole does not achieve CNS penetration by inhibiting P-glycoprotein. This is not its mechanism of CNS entry.
Option E: Option E is incorrect; while fluconazole does have in vitro and in vivo activity against Cryptococcus neoformans, the basis for choosing fluconazole over itraconazole for CNS consolidation is pharmacokinetic (superior CSF penetration), not intrinsically superior antifungal potency at equivalent plasma concentrations.
11. A patient with disseminated histoplasmosis is started on itraconazole oral solution 200 mg twice daily. The prescribing clinician plans to obtain a trough concentration to guide therapy. Which statement correctly describes the timing, target, and interpretation of itraconazole therapeutic drug monitoring (TDM) in this clinical context?
A) The trough sample should be drawn at steady state after at least 14 days of therapy; the therapeutic target for treatment of invasive fungal infection is a combined itraconazole plus hydroxy-itraconazole (the principal active metabolite) trough concentration above 1.0 mcg/mL, with concentrations above 10 mcg/mL associated with increased toxicity including hepatotoxicity and heart failure exacerbation
B) The trough sample should be drawn on day 3 of therapy to allow early dose adjustment before tissue distribution is complete; targeting a day-3 trough above 0.5 mcg/mL predicts steady-state therapeutic adequacy with high sensitivity
C) TDM should only be performed if the patient fails to show clinical improvement after four weeks; a therapeutic trough target is not established for itraconazole and drug concentrations are interpreted qualitatively rather than against a defined threshold
D) The trough target for itraconazole is above 2.0 mcg/mL for treatment of any invasive fungal infection; concentrations between 1.0 and 2.0 mcg/mL are subtherapeutic and predict treatment failure in histoplasmosis even in immunocompetent patients
E) TDM measures only the parent itraconazole compound because hydroxy-itraconazole is pharmacologically inactive; a trough above 0.5 mcg/mL of parent drug alone is the established therapeutic threshold for treatment
ANSWER: A
Rationale:
Option A is correct. Itraconazole TDM is recommended routinely for treatment of invasive fungal infections because of high interpatient pharmacokinetic variability driven by CYP3A4 polymorphism, variable food and pH effects on absorption, and drug interactions. Trough concentrations must be drawn at steady state — itraconazole has a half-life of 24 to 42 hours (extending further with prolonged use as tissue compartments saturate), and steady state requires approximately 14 days of continuous therapy. Samples drawn before steady state will substantially underestimate the eventual steady-state exposure and lead to unnecessary dose escalation. The therapeutic target for treatment of invasive fungal infections is a combined itraconazole plus hydroxy-itraconazole trough concentration above 1.0 mcg/mL (the prophylaxis target is above 0.5 mcg/mL). Standard HPLC (high-performance liquid chromatography) assays report both itraconazole and its principal active metabolite hydroxy-itraconazole together; interpreting the combined concentration against the 1.0 mcg/mL threshold is correct clinical practice. Concentrations above 10 mcg/mL are associated with hepatotoxicity and may worsen or precipitate heart failure.
Option B: Option B is incorrect; day-3 concentrations are not at steady state and cannot reliably predict steady-state exposure. Drawing a trough before 14 days will underestimate equilibrium drug levels and is not the recommended TDM timing.
Option C: Option C is incorrect; TDM is recommended routinely, not only after clinical failure. A defined therapeutic threshold (combined trough above 1.0 mcg/mL for treatment) is established and guides dose adjustment. Waiting four weeks before checking a level risks prolonged subtherapeutic exposure.
Option D: Option D is incorrect; the established therapeutic target for treatment of invasive fungal infection with itraconazole is above 1.0 mcg/mL (combined), not above 2.0 mcg/mL. A combined trough between 1.0 and 2.0 mcg/mL is within the therapeutic range, not subtherapeutic.
Option E: Option E is incorrect; standard itraconazole TDM assays measure both itraconazole and hydroxy-itraconazole together because hydroxy-itraconazole is pharmacologically active with antifungal potency comparable to the parent compound. Excluding the active metabolite would systematically underestimate total antifungal drug exposure.
12. A 58-year-old patient with hematologic malignancy on fluconazole prophylaxis develops candidemia. Blood cultures identify Candida glabrata (now reclassified as Nakaseomyces glabratae). Susceptibility testing is pending. The team asks whether fluconazole can be continued as empirical therapy while results are awaited. Which response reflects the correct prescribing framework?
A) Fluconazole prophylaxis failure in a patient with subsequent C. glabrata candidemia is not predictive of resistance; the prophylactic and treatment doses are pharmacologically distinct, and empirical fluconazole at 800 mg daily is appropriate while susceptibility results are pending
B) Candida glabrata is uniformly resistant to all azoles, making echinocandin therapy mandatory in every case; susceptibility testing for azoles is unnecessary and should not be requested
C) Candida glabrata has azole resistance rates of 10 to 30% in many centers, and resistance is further enriched in patients who develop breakthrough infection on azole prophylaxis; echinocandin therapy should be initiated empirically while susceptibility results are awaited, with step-down to fluconazole reserved for clinically stable patients with confirmed susceptible isolates and negative follow-up blood cultures
D) Candida glabrata resistance to fluconazole is exclusively mediated by ERG11 point mutations that only emerge after 10 to 14 days of treatment-dose azole exposure; since this patient was on prophylactic (low) doses, resistance is unlikely and empirical fluconazole is safe
E) The species identification of C. glabrata alone is sufficient to confirm echinocandin resistance; all C. glabrata isolates should be treated with liposomal amphotericin B rather than echinocandins due to the high probability of FKS (glucan synthase subunit) mutations in hospitalized patients
ANSWER: C
Rationale:
Option C is correct. Candida glabrata has the highest azole resistance rates among common Candida species causing bloodstream infections, driven primarily by CDR1 and CDR2 ABC efflux transporter overexpression and secondarily by ERG11 mutations. Fluconazole resistance rates of 10 to 30% are documented in many center-specific surveillance programs, and the proportion of susceptibility-dose-dependent (SDD) isolates is even higher. Critically, breakthrough candidemia developing during fluconazole prophylaxis substantially enriches the probability of a resistant isolate — prior azole exposure is a strong risk factor for resistance. Current IDSA guidelines recommend initiating echinocandin therapy empirically for all C. glabrata candidemia, with step-down to fluconazole considered only in clinically stable patients with confirmed fluconazole-susceptible isolates, negative follow-up blood cultures, and no prior azole exposure concerns. Continuing fluconazole empirically while awaiting susceptibility results in this patient risks treating an azole-resistant infection with an inactive agent.
Option A: Option A is incorrect; prophylaxis failure with fluconazole in a patient who subsequently develops C. glabrata candidemia strongly predicts azole resistance. The step from prophylactic to treatment doses does not overcome the resistance mechanism, which is efflux pump-mediated and present at baseline.
Option B: Option B is incorrect; Candida glabrata is not uniformly resistant to all azoles. Susceptibility testing is essential because a substantial proportion of isolates are susceptible, allowing eventual step-down to fluconazole in eligible patients.
Option D: Option D is incorrect; C. glabrata resistance to fluconazole is frequently present at baseline via constitutive CDR1/CDR2 efflux pump expression, not exclusively acquired through ERG11 mutations over 10 to 14 days of treatment-dose exposure. The mechanism is not dose-dependent induction; it is pre-existing efflux-mediated resistance.
Option E: Option E is incorrect; Candida glabrata does not have uniformly high rates of echinocandin resistance (FKS mutations), and echinocandins remain the first-line treatment for C. glabrata candidemia per current guidelines. Liposomal amphotericin B is an alternative, not the preferred agent, and this option inverts the appropriate treatment hierarchy.
13. A 66-year-old woman with known QTc prolongation at baseline (QTc 462 ms), hypokalemia, and methadone therapy for chronic pain requires fluconazole 400 mg daily for cryptococcal meningitis consolidation. The team considers the cardiac risk. Which statement most precisely characterizes fluconazole's mechanism of QTc prolongation and the risk factors that amplify it?
A) Fluconazole causes QTc prolongation exclusively through CYP3A4 inhibition, raising plasma concentrations of co-administered QT-prolonging drugs such as methadone; fluconazole itself has no direct cardiac electrophysiological effect at any dose
B) Fluconazole directly blocks the hERG (human ether-a-go-go-related gene) cardiac potassium channel, which conducts the rapid delayed rectifier potassium current (IKr) responsible for phase 3 ventricular repolarization; QTc prolongation is dose-dependent and is amplified by hypokalemia, hypomagnesemia, female sex, baseline QTc prolongation, bradycardia, and co-administration of other QT-prolonging drugs — all of which are present in this patient
C) Fluconazole prolongs the QTc interval by activating L-type calcium channels in ventricular cardiomyocytes, prolonging the action potential plateau phase; this mechanism is dose-independent and equally present at 100 mg and 800 mg daily
D) Fluconazole causes QTc prolongation through aldosterone pathway inhibition, reducing potassium reabsorption in the distal nephron; the resulting hypokalemia secondarily prolongs the QTc interval; the direct antifungal effect and the cardiac effect share the same CYP51 inhibition mechanism
E) Fluconazole's QTc risk is clinically significant only in patients with congenital long QT syndrome; in patients with acquired QTc prolongation from other causes such as methadone, fluconazole does not add meaningful additional risk because the hERG channel is already maximally inhibited by the co-administered agent
ANSWER: B
Rationale:
Option B is correct. Fluconazole directly blocks the hERG (human ether-a-go-go-related gene) potassium channel, which underlies the rapid delayed rectifier potassium current (IKr). IKr is a critical repolarizing current during phase 3 of the cardiac action potential; its inhibition slows ventricular repolarization, prolongs the QTc interval, and creates conditions for early afterdepolarizations and torsades de pointes (TdP), a potentially fatal polymorphic ventricular tachycardia. This effect is dose-dependent and most prominent at doses of 400 mg or above. The risk is substantially amplified by multiple factors present in this patient: female sex (women have longer baseline QTc and greater IKr sensitivity to drug blockade), hypokalemia (reduced extracellular potassium increases hERG block by reducing the driving force for channel recovery), baseline QTc prolongation (less reserve before reaching the threshold for TdP), and methadone co-administration (methadone is itself a potent hERG channel blocker, adding to fluconazole's IKr inhibition). Additionally, fluconazole inhibits CYP3A4 moderately, which can further increase methadone plasma concentrations, compounding the QTc risk through a pharmacokinetic mechanism. This patient has multiple high-risk features; ECG monitoring and electrolyte correction are essential, and the risk-benefit decision requires explicit consideration.
Option A: Option A is incorrect; fluconazole does have direct cardiac electrophysiological effects via hERG channel blockade, independent of CYP-mediated interactions with co-administered drugs. CYP3A4 inhibition raising methadone levels is a contributing factor but does not account for fluconazole's entire QTc risk.
Option C: Option C is incorrect; fluconazole does not cause QTc prolongation via L-type calcium channel activation. L-type calcium channel opening would prolong the plateau phase, but this is not fluconazole's mechanism; its effect is on the hERG repolarizing potassium channel during phase 3.
Option D: Option D is incorrect; fluconazole does not cause QTc prolongation through aldosterone pathway inhibition or indirect renal potassium wasting. While hypokalemia from any cause amplifies QTc risk, fluconazole's primary cardiac mechanism is direct hERG channel blockade, not renal potassium loss.
Option E: Option E is incorrect; hERG channel blockade is not an all-or-nothing mechanism that reaches a maximum with one drug. Multiple hERG-blocking drugs act additively on IKr inhibition; combining fluconazole with methadone (also a potent hERG blocker) increases the total degree of IKr suppression, worsening QTc prolongation beyond what either drug causes alone.
14. A patient with HIV (human immunodeficiency virus) is receiving a rifampin-based tuberculosis (TB) treatment regimen and develops progressive pulmonary histoplasmosis requiring systemic antifungal therapy. Itraconazole oral solution is considered. After two weeks of itraconazole 200 mg twice daily, the steady-state trough concentration is reported as less than 0.05 mcg/mL. Which mechanistic explanation accounts for this finding, and what is the correct clinical response?
A) Rifampin induces P-glycoprotein expression in the intestinal wall, increasing itraconazole efflux from enterocytes and selectively reducing oral bioavailability without affecting systemic clearance; switching to IV itraconazole would resolve the interaction
B) Rifampin competitively inhibits itraconazole binding to hepatic albumin, displacing itraconazole into the free fraction and accelerating renal clearance; co-administration causes a transient reduction in trough concentrations that resolves after four weeks of combined therapy
C) Rifampin inhibits CYP3A4 in the intestinal wall but induces CYP3A4 in the liver, creating a net pharmacokinetic effect that is unpredictable; the subtherapeutic trough may normalize with dose escalation to 400 mg twice daily
D) Rifampin chelates the triazole nitrogen of itraconazole in the gastric lumen, forming a poorly absorbed complex; administering itraconazole and rifampin six hours apart would prevent the interaction and allow therapeutic itraconazole levels to be achieved
E) Rifampin is a potent inducer of CYP3A4 (cytochrome P450 3A4) via activation of the pregnane X receptor (PXR), dramatically upregulating both intestinal and hepatic CYP3A4 expression; because itraconazole is primarily metabolized by CYP3A4, co-administration with rifampin accelerates itraconazole elimination so severely that plasma concentrations fall to near-zero — this combination is essentially contraindicated, and alternative antifungal therapy (such as amphotericin B induction or a rifampin-sparing TB regimen) must be considered
ANSWER: E
Rationale:
Option E is correct. Rifampin (rifampicin) is among the most potent inducers of CYP3A4 known in clinical pharmacology, acting through activation of the pregnane X receptor (PXR), which upregulates CYP3A4 transcription in both intestinal enterocytes and hepatocytes. Itraconazole is a CYP3A4 substrate dependent on this enzyme for its primary metabolic clearance; rifampin-induced CYP3A4 increases itraconazole's first-pass metabolism (reducing bioavailability from the oral solution) and accelerates systemic clearance simultaneously. The combined effect can reduce itraconazole plasma concentrations to near zero, as demonstrated by the trough below 0.05 mcg/mL — far below the treatment threshold of above 1.0 mcg/mL. Additionally, rifampin induces P-glycoprotein, further reducing intestinal absorption. This combination is essentially contraindicated. In clinical practice, managing simultaneous TB and histoplasmosis requires either substituting a rifampin-sparing TB regimen (e.g., replacing rifampin with a rifabutin-based regimen where interaction is less severe, though still present), or treating with amphotericin B induction for histoplasmosis during the intensive phase of TB therapy.
Option A: Option A is incorrect; while rifampin does induce P-glycoprotein and this does reduce oral itraconazole absorption, the predominant mechanism of the interaction is CYP3A4 induction reducing both first-pass and systemic CYP3A4-mediated metabolism. Switching to IV itraconazole would partially bypass first-pass but would not resolve the systemic CYP3A4 induction that continues to accelerate itraconazole elimination.
Option B: Option B is incorrect; rifampin is a CYP3A4 inducer, not a protein binding displacer. The mechanism of the interaction is enzymatic induction causing accelerated itraconazole metabolism, not albumin displacement accelerating renal clearance.
Option C: Option C is incorrect; rifampin induces CYP3A4 in both the intestinal wall and the liver — it is not an inhibitor of intestinal CYP3A4. The net pharmacokinetic effect is consistent and predictable: dramatically reduced itraconazole exposure. Dose escalation to 400 mg twice daily has been studied but does not reliably restore therapeutic concentrations in the presence of full-dose rifampin.
Option D: Option D is incorrect; chemical chelation of itraconazole's triazole nitrogen by rifampin in the gastric lumen does not occur. The interaction is entirely enzymatic (CYP3A4 induction) and separating administration times by six hours does not circumvent an enzyme induction effect, which operates continuously and is not a luminal drug-drug interaction.
15. A patient completing a three-month course of itraconazole oral solution for toenail onychomycosis asks how long itraconazole will remain in the nails after the last dose. The clinician explains that itraconazole persists in nail tissue long after plasma concentrations have fallen. Which pharmacokinetic properties of itraconazole account for both its extensive nail accumulation and the prolonged terminal elimination phase seen after prolonged therapy?
A) Itraconazole is water-soluble and distributes preferentially into aqueous compartments including nails, which have high water content; prolonged nail retention results from slow passive diffusion out of this aqueous reservoir back into plasma
B) Itraconazole is renally excreted unchanged and accumulates in nail tissue by the same tubular secretion mechanism that concentrates drugs in the renal medulla; prolonged retention reflects slow tubular reabsorption from the nail matrix
C) Itraconazole has low lipophilicity and minimal protein binding, allowing free drug to accumulate in poorly vascularized tissues such as nails by passive diffusion; the long half-life after prolonged therapy reflects slow re-equilibration from these avascular compartments
D) Itraconazole is highly lipophilic and approximately 99.8% protein-bound, giving it a large volume of distribution of approximately 11 L/kg; massive accumulation in lipophilic tissues including skin, nails, and adipose tissue serves as a reservoir that sustains nail concentrations long after plasma levels decline, and the terminal elimination half-life of 24 to 42 hours after short courses extends substantially further as tissue depots equilibrate during prolonged therapy
E) Itraconazole undergoes extensive enterohepatic recirculation after hepatic metabolism; bile-to-intestinal reabsorption cycling maintains plasma concentrations for weeks after the last dose, and nail tissue concentrations are maintained by continuous redistribution from the systemic circulation during this period
ANSWER: D
Rationale:
Option D is correct. Itraconazole is highly lipophilic and approximately 99.8% protein-bound, with a volume of distribution of approximately 11 L/kg — a value reflecting massive distribution into lipophilic tissues throughout the body, including skin, nails, lungs, liver, and adipose tissue. In these compartments, itraconazole concentrations may exceed simultaneous plasma concentrations by factors of 10 to 100 or more. Nails, which are keratinous lipophilic structures, accumulate itraconazole substantially, and nail concentrations remain detectable for six to nine months after completing a course of therapy — far longer than plasma concentrations are detectable. The clinical implication is that itraconazole for onychomycosis achieves its therapeutic effect not by maintaining constant plasma exposure throughout the treatment period, but by establishing a tissue reservoir from which drug is slowly released over months. The terminal elimination half-life of 24 to 42 hours seen after short courses extends significantly with prolonged therapy as the large peripheral tissue compartments equilibrate; drug re-entering the central compartment from these depots sustains elimination for an extended period.
Option A: Option A is incorrect; itraconazole is not water-soluble. It is one of the most lipophilic antifungal agents in clinical use. Its tissue accumulation is driven by lipophilicity and protein binding, not affinity for aqueous compartments. Nails are keratinous (lipophilic), not an aqueous reservoir.
Option B: Option B is incorrect; itraconazole is not renally excreted unchanged — it is extensively metabolized by hepatic CYP3A4. Less than 1% of the administered dose appears in urine as unchanged drug. Tubular secretion and medullary accumulation are not the mechanisms of nail retention.
Option C: Option C is incorrect; this description inverts itraconazole's actual pharmacokinetic properties. Itraconazole has high lipophilicity and high protein binding — not low lipophilicity and minimal protein binding. The correct mechanism of nail accumulation and prolonged retention is the lipophilic tissue reservoir, not free-drug diffusion into avascular tissue.
Option E: Option E is incorrect; itraconazole does not undergo clinically significant enterohepatic recirculation. Its prolonged tissue retention is due to redistribution from lipophilic tissue depots, not bile-intestinal cycling.
16. A clinical mycology laboratory characterizes two Candida albicans isolates from the same patient taken six weeks apart during fluconazole therapy. Isolate 1 (baseline) was fluconazole-susceptible. Isolate 2 (six weeks later) shows fluconazole MIC of 64 mcg/mL, voriconazole MIC of 0.12 mcg/mL, and itraconazole MIC of 0.06 mcg/mL. Molecular analysis identifies upregulation of the MDR1 gene encoding the Mdr1p transporter, driven by a gain-of-function MRR1 transcription factor gene mutation, with no CDR1 or CDR2 upregulation and no ERG11 point mutations detected. Which statement best distinguishes the resistance mechanism in this isolate from CDR1/CDR2-mediated resistance?
A) MDR1/Mdr1p upregulation and CDR1/CDR2 upregulation produce identical resistance profiles because both transporter families export all azole class members with equivalent efficiency; the molecular analysis findings do not explain the selective fluconazole resistance observed
B) Mdr1p is a member of the MFS (major facilitator superfamily) of drug efflux transporters and uses the proton motive force rather than ATP hydrolysis for energy; critically, its substrate specificity within the azole class is predominantly for fluconazole rather than voriconazole or itraconazole, explaining the fluconazole-selective resistance with retained susceptibility to other azoles — a pattern that would not be seen with CDR1/CDR2 upregulation, which confers cross-resistance to the entire azole class
C) Mdr1p is an ABC (adenosine triphosphate-binding cassette) transporter like CDR1 and CDR2, but its expression is regulated by the MRR1 transcription factor rather than TAC1; both resistance mechanisms produce pan-azole resistance, but MRR1-driven resistance has a higher MIC ceiling than TAC1-driven resistance
D) MDR1 upregulation confers fluconazole resistance by sequestering the drug in the fungal vacuole rather than exporting it across the plasma membrane; this mechanism accounts for the selective fluconazole resistance because voriconazole and itraconazole are too large to fit in the vacuolar compartment
E) MDR1 and CDR1/CDR2 resistance differ only in the chromosomal location of their respective genes; both encode plasma membrane efflux transporters with identical substrate specificity for all azoles, and the selective fluconazole resistance in this isolate must reflect an additional undetected ERG11 mutation not captured by the sequencing assay
ANSWER: B
Rationale:
Option B is correct. The Mdr1p transporter (encoded by MDR1 in Candida albicans) is a member of the major facilitator superfamily (MFS) of drug transporters — a protein family that uses the proton motive force (electrochemical proton gradient across the plasma membrane) for energy, in contrast to the ABC (adenosine triphosphate-binding cassette) transporters CDR1 and CDR2, which use ATP hydrolysis. Beyond this structural and energetic distinction, the most clinically important difference is substrate specificity within the azole class: Mdr1p preferentially exports fluconazole but does not efficiently export voriconazole or itraconazole. Gain-of-function MRR1 transcription factor gene mutations constitutively activate MDR1 expression, producing stable fluconazole-specific resistance as seen in isolate 2 — dramatically elevated fluconazole MIC with retained voriconazole and itraconazole susceptibility. By contrast, CDR1 and CDR2 overexpression, driven by gain-of-function TAC1 mutations, confers cross-resistance to the entire azole class because these ABC transporters export fluconazole, voriconazole, and itraconazole. This mechanistic distinction has a direct clinical implication: in a patient with MDR1-mediated fluconazole resistance, switching to voriconazole may remain effective because the resistance mechanism does not export voriconazole.
Option A: Option A is incorrect; MDR1/Mdr1p and CDR1/CDR2 do not produce identical resistance profiles. The defining difference — fluconazole-selective resistance with MDR1 vs. pan-azole cross-resistance with CDR1/CDR2 — is mechanistically established and directly explains the susceptibility pattern in this isolate.
Option C: Option C is incorrect; Mdr1p is not an ABC transporter. It is an MFS transporter using the proton motive force. CDR1 and CDR2 are the ABC transporters. Furthermore, MDR1 upregulation does not produce pan-azole resistance; it produces fluconazole-selective resistance.
Option D: Option D is incorrect; Mdr1p does not sequester drug in the fungal vacuole. It is a plasma membrane efflux transporter that exports fluconazole out of the fungal cell. Vacuolar drug sequestration has been proposed for some compounds but is not the established mechanism of Mdr1p-mediated azole resistance.
Option E: Option E is incorrect; MDR1 and CDR1/CDR2 encode transporters in structurally distinct protein families with different substrate specificities. The selective fluconazole resistance pattern is fully explained by MDR1 upregulation alone and does not require an undetected ERG11 mutation.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.